ARIA Related New Coverage
-
Goldman Sachs Starts ARIAD Pharmaceuticals (ARIA) at Neutral
-
JMP Securities Starts ARIAD Pharmaceuticals (ARIA) at Market Outperform
-
Guggenheim Starts ARIAD Pharmaceuticals (ARIA) at Buy
-
Citi Starts ARIAD Pharmaceuticals (ARIA) at Buy
-
William Blair Starts ARIAD Pharma (ARIA) at Outperform, $25 Target
-
UPDATE - UBS Initiates Coverage on Ariad Pharma (ARIA) with a Buy; Ponatinib Can Be A Billion Dollar Drug
-
UBS Starts BMRN, RDEA, ARIA at Buy, ITMN, ACHN, HGSI, IRWD at Neutral
-
Stifel Nicolaus Initiates/Restarts BIIB, AFFY, CELG, GILD, ACOR, ARQL, ARIA, EXEL, BSTC at Buy, AMGN, DNDN at Hold
-
RBC Capital Starts ARIAD Pharmaceuticals (ARIA) at Outperform
-
Maxim Group Starts ARIAD Pharmaceuticals (ARIA) at Buy
-
Rodman & Renshaw Starts ARIAD Pharmaceuticals (ARIA) at Market Outperform
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Summer Street Starts ARIAD Pharmaceuticals (ARIA) at Buy
-
Monness, Crespi, Hardt Starts ARIAD Pharma (ARIA) at Buy, $22 Price Target
-
BofA/Merrill Lynch Starts ARIAD Pharmaceuticals (ARIA) at Neutral
-
Brean Murray Carret & Co. Assumes Coverage on ARIAD Pharmaceuticals (ARIA) at Buy, $11 Price Target
-
Williams Capital Starts ARIAD Pharmaceuticals (ARIA) at Outperform
-
Brean Murray Initiates Coverage on Ariad Pharmaceuticals (ARIA) with a Hold; Strong Fundamentals, Cautious on Phase 3 Trial
-
Oppenheimer Initiates Coverage on ARIAD Pharmaceuticals (ARIA) with an Outperform
-
Susquehanna Initiates Coverage on Ariad Pharmaceuticals (ARIA) with a Positive
-
Jefferies & Co Initiates Coverage on ARIAD Pharmaceuticals (ARIA) with a Buy
-
Jefferies & Co Initiates Coverage on Ariad Pharma (ARIA) with a Buy
-
Leerink Swann Initiates ARIA
-
Banc of America Initiates Coverage on a Number of Biotech Stocks
-
Oppenheimer Started ARIA at Buy
-
Bear Stearns Starts ARIA at Outperform
-
Adams Harkness Re-Launches Coverage of Biotech Sector
Back to ARIA Stock Lookup
